Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
Mobility
Jahr
Publikationsjahr
2019
Autoren
Autorenliste der Publikation
Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, Kern R, Ziemssen T.
Verlag
Publisher-Information
Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/2040622319835136
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Mobilität
Treatments
2019
MOBI
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis
Other
Jahr
2024
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice
Multiple Sclerosis
Jahr
2024
MS brain health quality standards: a survey on the reality in clinical practice in Germany
Multiple Sclerosis
Jahr
2024
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
2024
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Multiple Sclerosis
Jahr
2024
